Bilayer PPI-Antacid Formulation for Acid-Stable Rapid Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Proton pump inhibitors (PPIs) face stability and dissolution rate issues under acidic conditions, leading to decomposition and delayed drug action due to poor compatibility with excipients and enteric coatings.
Innovation Solution
A pharmaceutical composite formulation with a first layer containing a proton pump inhibitor, a disintegrant (crospovidone or sodium starch glycolate), and a binder (hydroxypropyl cellulose or hypromellose), and a second layer with an antacid (magnesium hydroxide or magnesium oxide), designed to release the antacid first, neutralizing gastric acid and then the proton pump inhibitor.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If enteric coating is used to protect proton pump inhibitor from acid decomposition, then stability is improved, but device complexity and manufacturing complexity increase
Solution Approach 1:
The tablet is divided into two distinct layers: a first layer containing the proton pump inhibitor and a second layer containing the antacid. This segmentation allows each layer to have optimized properties without requiring complex enteric coatings, thereby improving stability while reducing manufacturing complexity
Solution Approach 2:
The antacid layer acts as an intermediary that neutralizes gastric acid before the proton pump inhibitor is released. This mediator approach protects the acid-sensitive PPI from decomposition without requiring protective coatings, simplifying the formulation
2Stability of the object's composition
If enteric coating is applied to stabilize proton pump inhibitor, then stability is improved, but dissolution rate decreases
Solution Approach 1:
By segmenting the tablet into two layers with different dissolution characteristics, the invention achieves both stability and rapid dissolution. The PPI layer dissolves quickly without enteric coating, while the antacid layer provides protective acid neutralization
Solution Approach 2:
The antacid layer performs preliminary action by neutralizing gastric acid before the proton pump inhibitor is released into the stomach. This preliminary protection allows the PPI to maintain stability while achieving rapid dissolution without enteric coating barriers
3Stability of the object's composition
If excipients are added to stabilize proton pump inhibitor formulation, then stability is improved, but compatibility issues arise and drug efficacy is delayed
Solution Approach 1:
Separating the PPI and antacid into different layers eliminates compatibility issues between excipients and the acid-sensitive PPI. Each layer can use excipients optimized for its specific requirements without interfering with the other component's stability or efficacy
Solution Approach 2:
The antacid layer serves as a protective intermediary that creates a favorable environment for PPI stability through acid neutralization, rather than relying on complex excipient interactions that may cause compatibility problems
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation maintains stability, prevents acid degradation, and achieves rapid drug action by ensuring a time-differentiated release of the proton pump inhibitor and antacid, improving dissolution rates and reducing related substances.
Implementation Method 1
an antacid selected from magnesium hydroxide, magnesium oxide, or a mixture thereof
Data Source
AI summary
An aspect provides a pharmaceutical composite formulation containing: a first layer comprising a proton pump inhibitor or a pharmaceutically acceptable salt thereof as an active ingredient, a disintegrant, and a binder; and a second layer comprising, as an active ingredient, an antacid selected from magnesium hydroxide, magnesium oxide, or a mixture thereof.